RxDoctor Payments Data

Rebecca Pfabe, APRN

Nurse Practitioner · Lincoln, NENPI 1356357586

Payments from drug & device makers

$1,930in general payments, 2019–2025

Across 27 payments — averaging $71.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$445
  • Otsuka America Pharmaceutical, Inc.$292
  • Boston Scientific$258
  • AstraZeneca$178
  • Novo Nordisk$151
  • Bayer$133
  • plus $473 from 7 others

What the payments were for

  • Food & beverage$1,930100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,930 in reported general payments places this provider in the 80th percentile of 924 nurse practitioner providers in Nebraska.

See all nurse practitioner providers in Nebraska

Medicare billing

Part B allowed, 2024
$50,609
Medicare patients
223
Services billed
981

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide31$28,837
EliquisApixaban25$22,788
TrulicityDulaglutide23$22,635
XareltoRivaroxaban20$16,229
JardianceEmpagliflozin14$8,040
Advair HfaFluticasone Propion/Salmeterol15$4,512
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$1,856
Duloxetine Hcl63$1,592
Atorvastatin Calcium279$1,415
Levothyroxine Sodium189$1,338
Amlodipine Besylate171$996
Omeprazole84$884
Gabapentin48$835
Midodrine Hcl16$807
Albuterol Sulfate HfaAlbuterol Sulfate30$770

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$151$28,83731 claims
Johnson & JohnsonXarelto$72$16,22920 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 924 nurse practitioner providers in Nebraska.

Other nurse practitioner in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →